AASLD recommends that patients with NAFLD cirrhosis should be considered for HCC screening with ultrasound testing and with or without measurement of blood alpha-fetoprotein (AFP) levels, every 6 months [52, 61]. The gene discussed is AFP; the disease is metabolic dysfunction-associated steatotic liver disease.